ABAichetou Bouh

Aichetou Bouh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aichetou Bouh has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Chemotherapy-associated changes in nutritional status, body composition, biochemical parameters, and physical activity among cancer patients: insights from a prospective cohort study

    by Aichetou Bouh, Abderrahmane Moufid, Nouriya EL Ghoulam, Daoud Daoudi, Sihame Lkhoyaali, Zakaria El Hafi, Souad Benaich, Hassan Aguenaou, Slimane Mehdad, Saber Boutayeb

    Background: Chemotherapy is often associated with metabolic and functional disorders that may affect treatment outcomes in cancer patients. This study aimed to assess chemotherapy-induced changes in weight, body composition, nutritional status, biochemical parameters, and physical activity levels in Moroccan cancer patients. Methods: This prospective cohort study involved 422 cancer patients treated by chemotherapy. Anthropometric measurements and bioelectrical impedance analysis were used to assess weight status and body composition. Nutritional status was evaluated using the Nutritional Risk Index, and biochemical parameters were obtained from the hospital's database. Physical activity levels were assessed by the International Physical Activity Questionnaire. Results: After chemotherapy, there were significant reduction in fat-free mass and increase in body fat percentage (P < 0.001). The proportion of patients with moderate/severe malnutrition, sarcopenic obesity, and low muscle mass increased from 34.2%, 29.1%, and 49.1% pre-treatment to 50.0%, 39.3%, and 57.8% post-treatment, respectively. There was a significant decrease in total protein levels ( P = 0.034). Physical activity and total energy expenditure decreased after chemotherapy (P < 0.001). Younger age (<60 years), low/moderate physical activity levels, and excessive body fat were independently associated with weight gain. Short disease duration (<12 months) and normal nutritional status were protective against moderate/severe weight loss, while non-excessive body fat increased such weight alteration. Non-malnourished patients and those without excess body fat had higher odds for low muscle mass. Conclusions: Chemotherapy induced significant alterations in weight, nutritional status, body composition, and physical activity. Early implementation of nutritional and lifestyle interventions is needed in oncological care to prevent treatment-related malnutrition and adverse outcomes in cancer patients.

  • Open Access

    Moroccan Cannabis sativa L. seed chloroform extract: phytochemistry, acute toxicity, and metabolic-behavioral effects in mice

    by Fatima Zahra El Mskini, Anass Rami, Asmae Labyad, Hind Ibork, Zakaria Ait Lhaj, Ahmed Oubaasri, Abdelmounaim Laabar, Aichetou Bouh, Nouriya El Ghoulam, Rachida Hassikou, et al.

    Despite growing interest in the therapeutic use of Cannabis sativa L. following its legalization for medicinal purposes in 2021, the toxicity profile of its seeds remains largely underexplored in Morocco. This study aimed to characterize the phytochemical profile and acute oral toxicity of a chloroform seed extract (C/S) from Moroccan Cannabis sativa L. C/S extract (yield: 4.27 ± 0.13%) was analyzed by gas chromatography coupled with mass spectrometry (GC-MS). Acute toxicity testing was performed according to OECD Test Guideline 425: female Swiss mice (n = 5/group) received a single 2,000 mg kg⁻¹ oral dose or vehicle control, followed by 14 d monitoring of clinical signs, body weight (BW), organ weight, and serum biochemistry (ASAT/ALAT, creatinine, urea, and lipid profile). GC-MS analysis revealed 16 compounds, with octacosane (6.80%), 2-methyloctadecane (5.75%), and cannabidiol (5.32%) as the major components. No treatment-related mortality was observed (LD₅₀ > 2,000 mg kg⁻¹), and only transient signs of hypoactivity/tachycardia were noted, which resolved spontaneously within a few hours. BW gain (p = 0.154), liver/BW (p = 0.103), and kidney/BW (p = 0.406) ratios showed no significant differences. Total cholesterol was lower in the C/S group than in controls (0.82 ± 0.06 g L⁻¹ vs. 2.13 ± 0.38 g L⁻¹, p = 0.014), whereas LDL-C was higher in the C/S group (0.07 ± 0.00 g L⁻¹ vs. 0.03 ± 0.01 g L⁻¹, p = 0.002). The C/S extract demonstrated low acute toxicity under the tested conditions, supporting further safety-oriented pharmaceutical investigation of Moroccan Cannabis sativa L. seeds.


  • Open Access

    Prevalence and correlates of metabolic syndrome in type 2 diabetes patients: A cross sectional study at the provincial diabetes center in Meknes, Morocco

    by Daoud Daoudi, Nouriya Elghoulam, Nadia El Mahri, Aichetou Bouh, Youssef Aboussaleh, Abdellah Zinedine, Saber Boutayeb, Souad Benaich, Slimane Mehdad

  • Open Access

    Nutritional Status, Muscle Mass, and Body Fat Percentage in Patients with Breast Cancer Undergoing Adjuvant Chemotherapy

    by Aichetou Bouh, Slimane Mehdad, Nouriya El Ghoulam, Daoud Daoudi, Souad Benaich, Aicha Madkour, Hassan Errihani, Saber Boutayeb

    Aims: To evaluate alterations in weight, body composition, and nutritional parameters, and to identify the clinical, anthropometric, and dietary determinants of these changes among patients with breast cancer (BC) treated with adjuvant chemotherapy (AC). Methods: This study involved a cohort of 252 BC patients treated with AC. Anthropometric measurements were collected using standardized equipment and body composition was evaluated via bioelectrical impedance analysis (BIA). Clinical data were retrieved from the hospital's information system. Adherence to the Mediterranean Diet (MedDiet) was evaluated using a validated food frequency questionnaire. Results: Post-AC, 29.3% and 22.7% of patients experienced moderate/high weight gain (WG ≥ 5%) and moderate/severe weight loss (MSWL ≥ 5%), respectively. The prevalence of patients with low muscle mass (LMM) and sarcopenic obesity increased from 11.5% and 2.8% pre-treatment to 15.1% and 7.9% post-treatment, respectively. Younger women (aged 24 – 39 years) exhibited reduced odds of experiencing MSWL (OR = 0.31, 95%CI: 0.08 – 1.20) and LMM (OR = 0.19, 95%CI: 0.02 – 1.61) compared to those aged ≥ 60 years. Patients with BC stages I and II were associated with increased odds of WG (OR = 2.10, 95%CI: 0.44 – 9.89; and OR = 2.13, 95%CI: 0.46 – 9.68, respectively). Relative to obese individuals, normal-weight/underweight individuals exhibited a significantly higher likelihood of WG (OR = 2.29; 95%CI: 1.03 – 5.08) and MSWL (OR = 3.23, 95%CI: 1.19 – 8.80), but a lower likelihood of LMM (OR = 0.33, 95%CI: 0.13 – 0.87). The Anthracycline-Taxane and Monoclonal-antibodies-Taxane regimens were associated with higher odds of MSWL (OR = 3.64, 95%CI: 0.35 – 36.98, and OR = 2.63, 95%CI: 1.03 – 6.72, respectively). Low and moderate adherence to the MedDiet were independently associated with an elevated risk of both WG and MSWL. Conclusions: A substantial proportion of patients with BC experience significant weight fluctuation or deterioration in muscle mass following AC. These adverse outcomes are modulated by patient age, cancer stage or duration, baseline BMI, the specific chemotherapy regimen employed, and MeDiet adherence. Keywords: Adjuvant chemotherapy; Body composition; Body Mass Index; Breast cancer; Mediterranean diet; Weight change.

  • Open Access

    Nutritional Status, Muscle Mass, and Body Fat Percentage in Patients with Breast Cancer Undergoing Adjuvant Chemotherapy

    by Aichetou Bouh, Slimane Mehdad, Nouriya El Ghoulam, Daoud Daoudi, Souad Benaich, Aicha Madkour, Hassan Errihani, Saber Boutayeb

    Aims: To evaluate alterations in weight, body composition, and nutritional parameters, and to identify the clinical, anthropometric, and dietary determinants of these changes among patients with breast cancer (BC) treated with adjuvant chemotherapy (AC). Methods: This study involved a cohort of 252 BC patients treated with AC. Anthropometric measurements were collected using standardized equipment and body composition was evaluated via bioelectrical impedance analysis (BIA). Clinical data were retrieved from the hospital's information system. Adherence to the Mediterranean Diet (MedDiet) was evaluated using a validated food frequency questionnaire. Results: Post-AC, 29.3% and 22.7% of patients experienced moderate/high weight gain (WG ≥ 5%) and moderate/severe weight loss (MSWL ≥ 5%), respectively. The prevalence of patients with low muscle mass (LMM) and sarcopenic obesity increased from 11.5% and 2.8% pre-treatment to 15.1% and 7.9% post-treatment, respectively. Younger women (aged 24 – 39 years) exhibited reduced odds of experiencing MSWL (OR = 0.31, 95%CI: 0.08 – 1.20) and LMM (OR = 0.19, 95%CI: 0.02 – 1.61) compared to those aged ≥ 60 years. Patients with BC stages I and II were associated with increased odds of WG (OR = 2.10, 95%CI: 0.44 – 9.89; and OR = 2.13, 95%CI: 0.46 – 9.68, respectively). Relative to obese individuals, normal-weight/underweight individuals exhibited a significantly higher likelihood of WG (OR = 2.29; 95%CI: 1.03 – 5.08) and MSWL (OR = 3.23, 95%CI: 1.19 – 8.80), but a lower likelihood of LMM (OR = 0.33, 95%CI: 0.13 – 0.87). The Anthracycline-Taxane and Monoclonal-antibodies-Taxane regimens were associated with higher odds of MSWL (OR = 3.64, 95%CI: 0.35 – 36.98, and OR = 2.63, 95%CI: 1.03 – 6.72, respectively). Low and moderate adherence to the MedDiet were independently associated with an elevated risk of both WG and MSWL. Conclusions: A substantial proportion of patients with BC experience significant weight fluctuation or deterioration in muscle mass following AC. These adverse outcomes are modulated by patient age, cancer stage or duration, baseline BMI, the specific chemotherapy regimen employed, and MeDiet adherence. Keywords: Adjuvant chemotherapy; Body composition; Body mass index; Breast cancer; Mediterranean diet; Weight change.

  • Open Access

    Exploring the relationships of Metabolic Syndrome with sociodemographic factors, weight status, dietary and lifestyle behaviors in Moroccan adults

    by Daoud Daoudi, Abderrahmane Moufid, Nouriya Elghoulam, Aichetou Bouh, Khalid El Kari, Baha Rabi, Houda El Hsaini, Souad Benaich, Saber Boutayeb, Hassan Aguenaou, et al.


  • The use of medicinal plants by cancer patients receiving chemotherapy: A cross-sectional study at a referral oncology hospital in Morocco

    by Aichetou Bouh, Slimane Mehdad, Nouriya El Ghoulam, Daoud Daoudi, Ahmed Oubaasri, Fatima Zahra El Mskini, Asmae Labyad, Hinde Iraqi, Souad Benaich, Rachida Hassikou, et al.

    Background and aim: The high cost of cancer treatment and adverse side effects of drug therapy remain major health issues worldwide. Medicinal plants (MP) can be used to promote new, safe, and effective anticancer medications. This study aimed to estimate the prevalence of MP use among cancer patients, investigate its association with sociodemographic and clinical factors, and provide available information about the species used. Materials and methods: This was a cross-sectional study among 508 patients undergoing chemotherapy. Sociodemographic data and information on MPs used in cancer treatment were collected using face-to-face interviews and a questionnaire. Clinical data were obtained from the hospital database. Ethnobotanical indices, including relative citation frequency, informed consensus factor, and fidelity level, were determined for data analysis. Results: 43.2% of patients used MPs. Of these, 66.3% did not disclose information about MPs to their physicians, 54% experienced improvements, and 6% reported undesirable side effects associated with using MPs. There was a significant association of MPs use with disease duration ( P  = 0.037) and cancer type ( P  < 0.001). 27 plant species belonging to 17 families were identified, with Lamiaceae, Apiaceae, and Fabaceae being the most common. The most used species were Origanum compactum benth ., Marrubium vulgare L., Trigonella foenum-graecum L., Aloysia citriodora , and Rosmarinus officinalis L. Conclusion: This study showed a high prevalence of MPs use among patients undergoing chemotherapy. Although further studies are needed to investigate the efficacy and safety of commonly used species, our findings may be used to inform evidence-based guidelines, promote communication between cancer patients and healthcare providers, and develop new medicinal plants.


  • Open Access

    Epidemiological, clinical and evolutive profile of tuberculosis patients: Case of the region of Guelmim in Morocco

    by Ahmed Oubaasri, Asmae Labyad, Fatima Zahra El Mskini, Wafae Belokda, Aicha Madkour, Nouriya El Ghoulam, Daoud Daoudi, Aichetou Bouh, Slimane Mehdad, Souad Benaich